Method for detecting content of semi-volatile unknown substances in leaching liquor of medical apparatus and instruments based on dispersive liquid-liquid microextraction technology
The semi-volatile unknowns in the extract of medical devices were detected by dispersed liquid microextraction technology, which solved the problems of high cost and low efficiency in the prior art, and achieved efficient and low-cost detection effects.
Patent Information
- Application Number
- CN202411075919.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art uses a large amount of organic solvents when detecting the semi-volatile unknown substance content in the extract liquid of medical devices, which takes a long time, resulting in high cost and low efficiency, making it difficult to meet scientific research and market demands.
Using dispersed liquid microextraction technology, the internal standard mixed standard solution, extractant and cosolvent were prepared, combined with gas chromatography and mass spectrometer detection, the calibration curve was established, and the unknown content was qualitative and quantitatively analyzed, and the amount of sample leaching liquid was reduced. and extraction time.
It significantly reduces the use of organic solvents and operating time, reduces the number of samples, reduces the detection cost, improves the experimental efficiency, and meets the detection needs.
Smart Images

Figure CN118980759A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of material analysis and detection, and in particular to a method for detecting the content of semi-volatile unknown substances in a medical device extract based on a dispersed liquid-liquid microextraction technology. Background Art
[0002] Leachable substances are chemical substances released from medical devices during the process of continuous contact and function between medical device products and the human body, or when they interact with other media in use (such as liquid medicine, blood, etc.). They generally include sterilization residues, processing residues, degradation products, solvents, monomers and additives in materials (including stabilizers, antioxidants, plasticizers, colorants, etc.). While medical devices play a diagnostic and therapeutic role, leachable substances also pose a safety hazard to the human body in the short or long term. Therefore, the study of its safety is not only the focus of enterprises in the design and development stage of products, but also the focus of the technical review of related products.
[0003] In the practice of leachables testing, there are many practical challenges, such as the diverse and complex clinical contact routes and usage methods, and the ethical issues of clinical sample collection. For most devices, it is difficult to conduct a true study of leachables, and it is more appropriate to replace leachables research with extraction experiments.
[0004] In recent years, the analytical detection method for the content of extractables and leachables in medical device extracts is: use solvents of different polarities to extract medical device products, and the obtained extracts need to be solvent replaced, concentrated by nitrogen blowing, and then analyzed on the machine. This method has the following shortcomings: First, for water-based sample extracts such as water or ethanol water, solvent replacement is required, and dichloromethane is usually used, which results in a large amount of dichloromethane solvent used, which increases the cost, and requires shaking followed by nitrogen blowing and concentration, which is time-consuming and labor-intensive; secondly, for research projects with higher concentration multiples, more sample extracts are required, and more samples are required for extraction, and medical device products are expensive, which will greatly increase the research cost.
[0005] Therefore, this field needs to study a method that can detect the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology, reduce the use of organic solvents and shorten the operation time, greatly reduce the test cost, thereby improving detection efficiency and further meeting the needs of scientific research and the market. Summary of the invention
[0006] In order to solve the above technical problems, the present application provides a method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology, comprising the following steps:
[0007] Step 1, preparing an internal standard mixed standard solution, wherein the internal standard mixed standard solution includes acenaphthene-d10, di(2-ethylhexyl)phthalate-d4, o-toluenesulfonamide, N-ethylpyrrolidone and 1-methyl-2-pyrrolidone-d9;
[0008] Step 2, preparing a series of standard working solutions of N,N-dimethylpropionamide, wherein the series of standard working solutions of N,N-dimethylpropionamide include acenaphthene-d10, di(2-ethylhexyl)phthalate-d4, o-toluenesulfonamide, N-ethylpyrrolidone, 1-methyl-2-pyrrolidone-d9, N,N-dimethylpropionamide, 1-methyl-2-pyrrolidone, p-toluenesulfonamide, acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine, n-octadecane, dimethyl phthalate, lauryl lactam, hexadecanoic acid butyl ester, acetylcitrate tributyl and di(2-ethylhexyl)phthalate;
[0009] Step 3, preparing an extractant and a co-solvent, wherein the extractant is a mixed solution of dichloromethane and isopropanol, and the co-solvent is an ethanol aqueous solution;
[0010] Step 4, taking the sample extract, adding the internal standard mixed standard solution, and then adding water or a co-solvent, and mixing;
[0011] Step 5, quickly inject the extractant, centrifuge and take out the lower organic solvent and place it in a nitrogen blowpipe, repeat the above extraction operation twice, combine all the lower organic phases into the same nitrogen blowpipe, and concentrate with nitrogen blowpipe to obtain the sample solution to be tested;
[0012] Step 6: Use gas chromatography-mass spectrometry to detect N,N-dimethylpropionamide series standard working solutions and the sample solution to be tested, and establish a calibration curve using an internal standard method;
[0013] Step 7, obtaining the peak area of the unknown substance in the sample solution to be tested, performing qualitative and quantitative analysis, and obtaining the concentration of the unknown substance in combination with the calibration curve;
[0014] Step 8. Calculate the unknown content based on the unknown concentration. The calculation formula is as follows:
[0015]
[0016] Where:
[0017] C: concentration of unknown substance;
[0018] V: volume of extract;
[0019] n: number of medical devices extracted;
[0020] f: Concentration factor.
[0021] Specifically, in step 4, 0.5 mL of the sample extract is concentrated to 0.125 mL by nitrogen blowing to obtain the sample solution to be tested.
[0022] Specifically, in the internal standard mixed standard solution, the concentrations of acenaphthene-d10 and di(2-ethylhexyl)phthalate-d4 are both 2000 μg / mL, and the concentrations of o-toluenesulfonamide, N-ethylpyrrolidone and 1-methyl-2-pyrrolidone-d9 are all 5000 μg / mL.
[0023] Specifically, in the N,N-dimethylpropionamide series standard working solutions, the concentration gradients of N,N-dimethylpropionamide, 1-methyl-2-pyrrolidone and p-toluenesulfonamide are set to 0.5 μg / mL to 25 μg / mL, and the concentration gradients of acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine, n-octadecane, dimethyl phthalate, lauryl lactam, butyl hexadecanoate, tributyl acetylcitrate and di(2-ethylhexyl) phthalate are set to 0.2 μg / mL to 10 μg / mL.
[0024] Preferably, in the N,N-dimethylpropionamide series standard working solutions, the working solution concentrations of N,N-dimethylpropionamide, 1-methyl-2-pyrrolidone and p-toluenesulfonamide are 0.5 μg / mL, 2.5 μg / mL, 5.0 μg / mL, 12.5 μg / mL and 25 μg / mL, respectively; the working solution concentrations of acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine, n-octadecane, dimethyl phthalate, lauryl lactam, butyl hexadecanoate, tributyl acetylcitrate and di(2-ethylhexyl) phthalate are 0.2 μg / mL, 1.0 μg / mL, 2.0 μg / mL, 5.0 μg / mL and 10 μg / mL, respectively.
[0025] Specifically, in the N,N-dimethylpropionamide series standard working solutions, the concentrations of acenaphthene-d10 and di(2-ethylhexyl)phthalate-d4 are both 2 μg / mL; the concentrations of o-toluenesulfonamide, N-ethylpyrrolidone and 1-methyl-2-pyrrolidone-d9 are all 5 μg / mL.
[0026] Specifically, in the extractant, the volume ratio of dichloromethane to isopropanol is 1:1 to 1:3, preferably 1:2; in the co-solvent, the volume ratio of ethanol to water is 1:4 to 1:6, preferably 1:5.
[0027] Specifically, the usage ratio of the sample extract, the co-solvent and the extractant is 5:15:1.
[0028] Specifically, in step 5, the centrifugal condition is: centrifugation at 1000 r / min for 1 min.
[0029] Specifically, in step 4, the adding of water or a co-solvent means that when the sample extract is obtained by extracting the medical device product with 50% ethanol water as the extraction solvent, water is added; when the sample extract is obtained by extracting the medical device product with water as the extraction solvent, a co-solvent is added.
[0030] Specifically, in step 6, the gas chromatography conditions of the gas chromatograph-mass spectrometer are as follows: chromatographic column: Agilent DB-1 capillary column 30m×0.25mm×0.25μm; injection port temperature: 280°C; heating program: 40°C for 1 min, increase to 300°C at 10°C / min, and maintain for 10 min; carrier gas: helium, purity >99.999%; injection volume: 1.0μL; flow rate 1.0mL / min, non-split mode.
[0031] Specifically, in step 6, the gas chromatography-mass spectrometry conditions of the gas chromatography-mass spectrometer are: ion source: EI ion source; transfer line temperature 280°C; ion source temperature 230°C; quadrupole temperature: 150°C; ionization energy: 70 eV; solvent delay 4.5 min; monitoring mode: full scan mode.
[0032] Specifically, the internal standards corresponding to the compounds in the calibration curve are: the internal standard corresponding to N,N-dimethylpropionamide is N-ethylpyrrolidone, the internal standard corresponding to 1-methyl-2-pyrrolidone is 1-methyl-2-pyrrolidone-d9, the internal standard corresponding to p-toluenesulfonamide is o-toluenesulfonamide, the corresponding internal standards of laurolactam, n-octadecane, butyl hexadecanoate, tributyl acetylcitrate and di(2-ethylhexyl)phthalate are all di(2-ethylhexyl)phthalate-d4, and the corresponding internal standards of acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine and dimethyl phthalate are acenaphthene-d10.
[0033] The sample pretreatment method of the present invention has the following beneficial effects:
[0034] 1. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology provided by the present invention adopts dispersed liquid-liquid microextraction (DLLME) technology, which is more efficient and convenient than the existing traditional liquid-liquid extraction method, uses very little extraction solvent, and has a shorter extraction time. In addition, the volume of sample extract required for the same concentration multiple is also greatly reduced, thereby reducing the number of samples used for extraction, which can significantly reduce the detection cost and greatly reduce the extraction cost of medical devices.
[0035] 2. The method provided by the present invention for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology has a very short time required for nitrogen blowing and concentrating 0.5 mL of sample extract to 0.125 mL, which saves time and improves experimental efficiency while avoiding the loss of unknown substance content caused by excessive nitrogen blowing time. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is the total ion current diagram of the N,N-dimethylpropionamide series of internal standard working solutions;
[0037] Figure 2 It is the gas chromatogram of the blank solution (CW) under water extraction conditions;
[0038] Figure 3 It is the gas chromatogram of sample solution 1 (TW-1) under water extraction conditions;
[0039] Figure 4 It is the gas chromatogram of sample solution 2 (TW-2) under water extraction conditions;
[0040] Figure 5 It is the gas chromatogram of sample solution 3 (TW-3) under water extraction conditions;
[0041] Figure 6 It is the gas chromatogram of the blank solution (CEW) under the condition of 50% ethanol water extraction;
[0042] Figure 7 It is the gas chromatogram of sample solution 1 (TEW-1) extracted with 50% ethanol water;
[0043] Figure 8 It is the gas chromatogram of sample solution 2 (TEW-2) extracted with 50% ethanol water;
[0044] Fig. 9 It is the gas chromatogram of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0045] Fig.10 This is a schematic diagram of the calibration curve of N,N-dimethylpropionamide;
[0046] Fig.11 Schematic diagram of the calibration curve of 1-methyl-2-pyrrolidone;
[0047] Fig.12 is a schematic diagram of the calibration curve of p-toluenesulfonamide;
[0048] Fig.13 is a schematic diagram of the calibration curve of acetophenone;
[0049] Fig.14 is a schematic diagram of the calibration curve of benzothiazole;
[0050] Fig.15 This is a schematic diagram of the calibration curve of 2-ethylhexyl acrylate;
[0051] Fig.16 is a schematic diagram of the calibration curve of methyl benzoylformate;
[0052] Fig.17 is a schematic diagram of the calibration curve of diphenyl ether;
[0053] Fig.18 This is a schematic diagram of the calibration curve of di-tert-butyl-4-methylphenol;
[0054] Fig.19 This is a schematic diagram of the calibration curve of tetradecamethylcycloheptasiloxane;
[0055] Fig. 20 is a schematic diagram of the calibration curve of diphenylamine;
[0056] Fig.21 is a schematic diagram of the calibration curve of n-octadecane;
[0057] Fig. 22 is a schematic diagram of the calibration curve of dimethyl phthalate;
[0058] Fig.23 It is a schematic diagram of the calibration curve of laurolactam;
[0059] Fig.24 Schematic diagram of the calibration curve of butyl hexadecanoate;
[0060] Fig.25 This is a schematic diagram of the calibration curve of acetyl tributyl citrate;
[0061] Fig.26 This is a schematic diagram of the calibration curve of di(2-ethylhexyl) phthalate;
[0062] Fig. 27 This is the mass spectrum of the unknown substance at 10.763 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0063] Fig.28 is the mass spectrum of benzothiazole;
[0064] Fig.29 This is the mass spectrum of the unknown substance at 10.959 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0065] Fig.30 is the mass spectrum of cyclohexylcarboxamide;
[0066] Fig.31 This is the mass spectrum of the unknown substance at 11.540 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0067] Fig.32 is the mass spectrum of nonanoic acid;
[0068] Fig.33 This is the mass spectrum of the unknown substance at 11.904 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0069] Fig.34 is the mass spectrum of N,N-dibutylformamide;
[0070] Fig.35 This is the mass spectrum of the unknown substance at 13.746 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0071] Fig.36 is the mass spectrum of dimethyl phthalate;
[0072] Fig.37 This is the mass spectrum of the unknown substance at 16.323 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0073] Fig.38 is the mass spectrum of triallyl isocyanurate;
[0074] Fig.39 This is the mass spectrum of the unknown substance at 17.744 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0075] Fig.40 is the mass spectrum of tris(2-chloroethyl) phosphate;
[0076] Fig.41 This is the mass spectrum of the unknown substance at 17.877 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0077] Fig.42 is the mass spectrum of bis(2-chloro-1-methylethyl) 3-chloropropyl phosphate;
[0078] Fig.43This is the mass spectrum of the unknown substance at 19.053 min of sample solution 3 (TEW-3) extracted with 50% ethanol water;
[0079] Fig.44 This is the mass spectrum of 7,9-di-tert-butyl-1-oxaspiro[4.5]dec-6,9-diene-2,8-dione. DETAILED DESCRIPTION
[0080] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0081] The reagents used in the following examples are all commercial reagents unless otherwise specified.
[0082] Embodiment 1
[0083] This example shows that the method for detecting the content of semi-volatile unknown substances in the extract of medical devices based on dispersed liquid-liquid microextraction technology provided in this application is used to detect the content of semi-volatile unknown substances in the extract of medical device blood catheters. The specific process is as follows:
[0084] 1. Solution Preparation
[0085] 1.1 Preparation of internal standard mixed solution
[0086] 1.1.1 Internal standard stock solution: Weigh the five internal standard substances in Table 1 for preparation, including: e-d10 and
[0087] About 20 mg of DEHP-d4, about 50 mg of OTS, NEP and NMP-d9 were placed in the same 10 mL volumetric flask, diluted to the mark with dichloromethane, mixed well, and marked as ISTD.
[0088] 1.1.2 Internal standard intermediate stock solution: Accurately pipette 1 mL of ISTD into a 10 mL volumetric flask, dilute to the mark with dichloromethane, mix well, and mark as ISTD-1.
[0089] 1.1.3 Internal standard working solution: Accurately pipette 0.1 mL of ISTD-1 into a 10 mL volumetric flask, dilute to the mark with dichloromethane, mix well, and mark as ISTD-2.
[0090] Table 1: Five internal standard substances
[0091] Standard product name abbreviation CAS# Acenaphthene-d10 e-d10 15067-26-2 Di(2-ethylhexyl)phthalate-d4 DEHP-d4 93951-87-2 o-Toluenesulfonamide OTS 88-19-7 N-Ethylpyrrolidone NEP 2687-91-4 1-Methyl-2-pyrrolidone-d9 NMP-d9 185964-60-7
[0092] 1.2 Preparation of N, N-dimethylpropionamide series standard working solutions
[0093] 1.2.1N,N-dimethylpropionamide series standard stock solution:
[0094] Weigh the compounds in Table 2: about 100 mg each of N,N-dimethylpropionamide, 1-methyl-2-pyrrolidone, and p-toluenesulfonamide, and about 40 mg each of the remaining compounds into a 20 mL volumetric flask, dilute to the mark with dichloromethane, and shake well to obtain a standard stock solution, which is marked as SS#1.
[0095] Table 2: 17 kinds of standard substances
[0096]
[0097]
[0098] 1.2.2N,N-dimethylpropionamide series standard intermediate stock solution: Accurately pipette 1mL SS#1 into a 10mL volumetric flask, dilute to the mark with dichloromethane, mix well, and mark as SS#2. Accurately pipette 1mL SS#2 into a 10mL volumetric flask, dilute to the mark with dichloromethane, mix well, and mark as SS#3.
[0099] 1.2.3N,N-dimethylpropionamide series standard working solution:
[0100] The preparation process of L-1 is as follows: accurately measure 0.1 mL of SS#3 in a 10 mL volumetric flask, add 0.1 mL of ISTD-1, dilute to the mark with dichloromethane, and mix well;
[0101] The preparation process of L-2 is as follows: accurately measure 0.5 mL of SS#3 in a 10 mL volumetric flask, add 0.1 mL of ISTD-1, dilute to the mark with dichloromethane, and mix well;
[0102] The preparation process of L-3 is as follows: accurately measure 0.1 mL of SS#2 in a 10 mL volumetric flask, add 0.1 mL of ISTD-1, dilute to the mark with dichloromethane, and mix well;
[0103] The preparation process of L-4 is as follows: accurately measure 0.25mL SS#2 in a 10mL volumetric flask, add 0.1mL ISTD-1,
[0104] Add dichloromethane to volume and mix well;
[0105] The preparation process of L-5 is as follows: accurately measure 0.5mL SS#2 into a 10mL volumetric flask, add 0.1mL ISTD-1,
[0106] Make up to volume with dichloromethane and mix well.
[0107] 1.3 Extraction agent preparation:
[0108] Separately measure 100 mL of dichloromethane and 200 mL of isopropanol into the same beaker and mix well.
[0109] 1.4 Preparation of cosolvent:
[0110] Separately measure 10 mL of ethanol and 50 mL of water into the same beaker and mix well.
[0111] 1.5 Obtaining extract samples:
[0112] 1.5.1 Water extract: Take 5mL of the sample extract after water extraction, add 125μL of the internal standard working solution ISTD-2, and then add 15mL of the co-solvent, mix well, use a syringe to take 1mL of the extractant and quickly inject it, centrifuge it at 1000r / min for 1min, use another clean syringe to take out the lower layer of organic solvent and put it into the nitrogen blowpipe; use a syringe to take 1mL of the extractant to repeat the second extraction, take the lower layer after centrifugation, and combine the organic phase; use a syringe to take 1mL of the extractant to repeat the third extraction, take the lower layer after centrifugation, and combine the organic phase. Concentrate to 0.125mL with nitrogen blowpipe.
[0113] Three copies were prepared in parallel and labeled as TW-1, TW-2, and TW-3, respectively, to be analyzed on the machine.
[0114] 1.5.2 50% ethanol water extract: Take 5mL of the sample extract extracted with 50% ethanol water, add 125μL of the internal standard working solution ISTD-2, then add 15mL of water, mix well, use a syringe to take 1mL of the extractant and quickly inject it, centrifuge it at 1000r / min for 1min, use another clean syringe to take out the lower layer of organic solvent and place it in a nitrogen blowpipe; use a syringe to take 1mL of the extractant and repeat the second extraction, take the lower layer after centrifugation, and combine the organic phases; use a syringe to take 1mL of the extractant and repeat the third extraction, take the lower layer after centrifugation, and combine the organic phases. Concentrate to 0.125mL with nitrogen blow. Prepare 3 copies in parallel, marked as TEW-1, TEW-2, and TEW-3, and wait for analysis on the machine. 1.6 Preparation of blank extract:
[0115] 1.6.1 Water blank extract: Take 5mL of water, add 125μL of internal standard working solution ISTD-2, and then add 15mL of cosolvent, mix well, take 1mL of extractant with a syringe and quickly inject, centrifuge at 1000r / min for 1min, take out the lower layer of organic solvent with another clean syringe and put it into nitrogen blowpipe; take 1mL of extractant with a syringe and repeat the second extraction, take the lower layer after centrifugation, and combine the organic phase; take 1mL of extractant with a syringe and repeat the third extraction, take the lower layer after centrifugation, and combine the organic phase. Concentrate to 0.125mL with nitrogen blowpipe, marked as CW.
[0116] 1.6.2 50% ethanol water blank extract: Take 5mL 50% ethanol water solution, add 125μL internal standard working solution ISTD-2, then add 15mL water, mix well, take 1mL extractant with a syringe and quickly inject, centrifuge at 1000r / min for 1min, take out the lower layer of organic solvent with another clean syringe and put it into nitrogen blowpipe; take 1mL extractant with a syringe and repeat the second extraction, take the lower layer after centrifugation, and combine the organic phase; take 1mL extractant with a syringe and repeat the third extraction, take the lower layer after centrifugation, and combine the organic phase. Concentrate to 0.125mL with nitrogen blowpipe and mark it as CEW.
[0117] 2. Gas chromatography-mass spectrometry analysis conditions
[0118] 2.1 Gas chromatography conditions:
[0119] Chromatographic column: Agilent DB-1 capillary column 30m×0.25mm×0.25μm; injection port temperature: 280℃; heating program: 40℃ for 1min, then increase to 300℃ at 10℃ / min, and hold for 10min; carrier gas: helium, purity>99.999%;
[0120] Injection volume: 1.0 μL; flow rate: 1.0 mL / min, splitless mode.
[0121] 2.2 Mass spectrometry conditions:
[0122] Ion source: EI ion source; transfer line temperature 280°C; ion source temperature 230°C; quadrupole temperature: 150°C;
[0123] Ionization energy: 70 eV; solvent delay 4.5 min; monitoring mode: full scan mode.
[0124] 3. Gas chromatography-mass spectrometry for analysis and detection
[0125] 3.1 Use gas chromatography-mass spectrometry to detect N,N-dimethylpropionamide series standard working solutions, 50% ethanol water extract, water extract, 50% ethanol water blank extract, and water blank extract, and record the chromatograms;
[0126] 3.2 Analysis results Figure 1-9 As shown, the peak area of each standard in the N,N-dimethylpropionamide series standard working solution and the peak area of the unknown substance in each extract were obtained.
[0127] 4. Data Processing
[0128] Set integration: set the internal standard of N,N-dimethylpropionamide to N-ethylpyrrolidone, set the internal standard of 1-methyl-2-pyrrolidone to 1-methyl-2-pyrrolidone-d9, set the internal standard of p-toluenesulfonamide to o-toluenesulfonamide, set the internal standards of five compounds, including laurolactam, n-octadecane, butyl hexadecanoate, tributyl acetylcitrate, and di(2-ethylhexyl)phthalate to di(2-ethylhexyl)phthalate-d4, and set the internal standards of acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine, and dimethyl phthalate to acenaphthene-d10. After integration, the linear regression equations of the 17 compound lines were obtained, as shown in the following figure: Figure 10-26 The linear regression equation is shown in Table 3 below:
[0129] Table 3 Linear regression equations of N,N-dimethylpropionamide series of internal standard working solutions
[0130]
[0131]
[0132] 5. Calculate the concentration of unknown substances
[0133] Unknown substances in the extract are identified. Based on the qualitative results, alternative standards with the same or similar structure and properties are selected for quantification. The ratio of their response to the corresponding internal standard response is inserted into the calibration curve of the standard. The result multiplied by the corresponding internal standard concentration is the final measured concentration.
[0134] 6. Calculate the content of unknown substances
[0135] 6.1 Calculate the unknown content in the medical device product based on the calculated concentration of the unknown substance. The calculation formula is as follows:
[0136]
[0137] Where:
[0138] C: concentration of unknown substance;
[0139] V: volume of extract;
[0140] n: number of medical devices extracted;
[0141] f: Concentration multiple
[0142] 6.2 Take TEW-3, a 50% ethanol-water sample extraction solution, as an example. Fig. 9As shown in FIG. 1 , the gas chromatography-mass spectrometry analysis results of the TEW-3 sample extract solution of 50% ethanol water are shown. Nine unknown substances are selected for representative quantitative method description. The mass spectra of the nine unknown substances are shown in FIG. Figure 27-44 , the specific identification and quantitative results are shown in Table 4 below:
[0143] Table 4: Identification and quantification results of 9 unknowns in TEW-3, a 50% ethanol-water sample extract
[0144]
[0145] It can be seen that the method for detecting the content of semi-volatile unknown substances in medical device extracts based on DLLME technology provided in this embodiment can identify all semi-volatile compounds released by medical device products that are above the analytical threshold. Based on the DLLME dispersed liquid-liquid microextraction technology, the experimental efficiency is significantly improved, the detection accuracy is good, and at the same time, it can reduce laboratory costs, which is also beneficial to reducing the manpower and material costs of medical device manufacturers in the production and development verification process.
[0146] In summary, the above embodiments are only preferred embodiments of the present invention and are not intended to limit the protection scope of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology, characterized in that: The following steps are involved: Step 1, preparing an internal standard mixed standard solution, wherein the internal standard mixed standard solution includes acenaphthene-d10, di(2-ethylhexyl)phthalate-d4, o-toluenesulfonamide, N-ethylpyrrolidone and 1-methyl-2-pyrrolidone-d9; Step 2, preparing a series of standard working solutions of N,N-dimethylpropionamide, wherein the series of standard working solutions of N,N-dimethylpropionamide include acenaphthene-d10, di(2-ethylhexyl)phthalate-d4, o-toluenesulfonamide, N-ethylpyrrolidone, 1-methyl-2-pyrrolidone-d9, N,N-dimethylpropionamide, 1-methyl-2-pyrrolidone, p-toluenesulfonamide, acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine, n-octadecane, dimethyl phthalate, lauryl lactam, hexadecanoic acid butyl ester, acetylcitrate tributyl and di(2-ethylhexyl)phthalate; Step 3, preparing an extractant and a co-solvent, wherein the extractant is a mixed solution of dichloromethane and isopropanol, and the co-solvent is an ethanol aqueous solution; Step 4, taking the sample extract, adding the internal standard mixed standard solution, and then adding water or a co-solvent, and mixing; Step 5, quickly inject the extractant, centrifuge and take out the lower organic solvent and place it in a nitrogen blowpipe, repeat the above extraction operation twice, combine all the lower organic phases into the same nitrogen blowpipe, and concentrate with nitrogen blowpipe to obtain the sample solution to be tested; Step 6: Use gas chromatography-mass spectrometry to detect N,N-dimethylpropionamide series standard working solutions and the sample solution to be tested, and establish a calibration curve using an internal standard method; Step 7, obtaining the peak area of the unknown substance in the sample solution to be tested, performing qualitative and quantitative analysis, and obtaining the concentration of the unknown substance in combination with the calibration curve; Step 8. Calculate the unknown content based on the unknown concentration. The calculation formula is as follows: Where: C: concentration of unknown substance; V: volume of extract; n: number of medical devices extracted; f: Concentration factor.
2. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In the internal standard mixed standard solution, the concentrations of acenaphthene-d10 and di(2-ethylhexyl)phthalate-d4 are both 2000 μg / mL, and the concentrations of o-toluenesulfonamide, N-ethylpyrrolidone and 1-methyl-2-pyrrolidone-d9 are all 5000 μg / mL.
3. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In the N,N-dimethylpropionamide series standard working solutions, the concentration gradients of N,N-dimethylpropionamide, 1-methyl-2-pyrrolidone and p-toluenesulfonamide are set to 0.5 μg / mL to 25 μg / mL, and the concentration gradients of acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine, n-octadecane, dimethyl phthalate, lauryl lactam, butyl hexadecanoate, tributyl acetylcitrate and di(2-ethylhexyl) phthalate are set to 0.2 μg / mL to 10 μg / mL.
4. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In the extractant, the volume ratio of dichloromethane to isopropanol is 1:1 to 1:3, and in the co-solvent, the volume ratio of ethanol to water is 1:4 to 1:
6.
5. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: The dosage ratio of sample extract, co-solvent and extractant is 5:15:
1.
6. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In step 5, the centrifugal condition is: centrifugation at 1000 r / min for 1 min.
7. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In step 4, the adding of water or a solvent means that when the sample extract is obtained by extracting the medical device product with 50% ethanol water as the extraction solvent, water is added; when the sample extract is obtained by extracting the medical device product with water as the extraction solvent, a solvent is added.
8. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In step 6, the gas chromatography conditions of the gas chromatography-mass spectrometer are as follows: chromatographic column: Agilent DB-1 capillary column 30m×0.25mm×0.25μm; injection port temperature: 280°C; heating program: 40°C for 1 min, then increase to 300°C at 10°C / min, and hold for 10 min; Carrier gas: helium, purity > 99.999%; injection volume: 1.0 μL; flow rate: 1.0 mL / min, splitless mode.
9. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: In step 6, the gas chromatography-mass spectrometry conditions of the gas chromatography-mass spectrometer are: ion source: EI ion source; transfer line temperature 280° C.; ion source temperature 230° C.; quadrupole temperature: 150° C.; ionization energy: 70 eV; solvent delay 4.5 min; monitoring mode: full scan mode.
10. The method for detecting the content of semi-volatile unknown substances in medical device extracts based on dispersed liquid-liquid microextraction technology according to claim 1, characterized in that: The internal standards corresponding to the compounds in the calibration curve are: the internal standard corresponding to N,N-dimethylpropionamide is N-ethylpyrrolidone, the internal standard corresponding to 1-methyl-2-pyrrolidone is 1-methyl-2-pyrrolidone-d9, the internal standard corresponding to p-toluenesulfonamide is o-toluenesulfonamide, the corresponding internal standards of laurolactam, n-octadecane, butyl hexadecanoate, tributyl acetylcitrate and di(2-ethylhexyl)phthalate are all di(2-ethylhexyl)phthalate-d4, and the corresponding internal standards of acetophenone, benzothiazole, 2-ethylhexyl acrylate, methyl benzoylformate, diphenyl ether, di-tert-butyl-4-methylphenol, tetradecamethylcycloheptasiloxane, diphenylamine and dimethyl phthalate are acenaphthene-d10.
